Preventive Botox in your 20s and 30s

Can treating muscles early slow the formation of lines? What studies show, where the evidence is thin, and what to consider before starting young.

The idea behind prevention

Expression lines form where skin is folded thousands of times by the muscles underneath. Each contraction creases the skin; over years, collagen and elastin recover less completely, and a line that once appeared only with movement stays visible at rest. Preventive treatment builds on a simple thought: if a muscle contracts less forcefully, it folds the skin less, and the transition from a dynamic to a static line may be delayed. The mechanism is explained in our article on how Botox works.

What the studies show

The best-known evidence comes from small studies. In 2006, Binder described a pair of identical twins over 13 years: one had received regular botulinum toxin treatments of the forehead and frown area, the other only twice. The regularly treated twin showed fewer lines in these areas. Identical twins share their genes, which makes the comparison interesting, but it remains a report about two people.

A pilot study by Bonaparte and Ellis (JAMA Facial Plastic Surgery, 2015) measured skin properties in 43 women before and after treatment and found changes in elasticity and pliability in the treated areas. Long-term follow-ups of patients treated over many years have also supported the safety of repeated treatment. What is missing are large, randomized studies that follow young people over decades and measure whether preventive treatment changes how their skin ages.

Current evidence: the rationale is biologically plausible and early data points in the same direction, but the long-term benefit of starting in your 20s has not been proven in large trials.

When treatment can make sense

Age alone is not a good criterion. More relevant is what the physician sees: a strong frown muscle that leaves a faint line in the morning, forehead lines that remain briefly after raising the eyebrows, or very expressive features that already show early creasing. In these situations, a low dose in the frown area or on the forehead can be a reasonable option. Where no lines are visible, there is often little to treat, and the honest answer can be to wait.

Questions worth asking first

Is there something to treat? Preventive treatment targets early dynamic lines, not perfect skin.
What is the lowest effective dose? Young patients often need small doses, and a natural range of expression should remain.
What does a realistic plan look like? The effect is temporary, so prevention means repeated treatments over years. Cost and time belong in that decision.
What are the risks? They are the same as at any age: bruising, headache, and rarely a temporary drooping of the eyelid or brow.

Prevention is more than injections

Most visible skin aging in the face is linked to UV exposure, so daily sunscreen remains the most effective preventive step at any age (see UV radiation and photo-aging). A topical retinoid, adequate sleep and not smoking all have a stronger evidence base for long-term skin quality than any single injection. Botulinum toxin can complement these basics for expression lines, but it does not replace them.

A note on “frozen” faces

A frequent worry is that starting early leads to an unnatural look or to the need for ever higher doses. Neither is a necessary consequence. A preventive approach usually means lower doses, so that movement is softened rather than stopped. If muscles become slightly weaker over years of treatment, doses can often be reduced rather than increased. What should be avoided are very short intervals and top-ups shortly after a treatment, both to keep the face natural and to keep the risk of antibody formation low.

The regulatory frame

In the EU, botulinum toxin products for aesthetic use are approved for adults, with indications covering frown lines, crow’s feet and forehead lines. They are prescription medicines, and a treatment requires a medical consultation in which suitability, dose and alternatives are discussed. At HALO, that consultation is free and never obligatory.

References

Small R. Botulinum toxin injection for facial wrinkles. Am Fam Physician. 2014;90(3):168-175. PMID 25077722.
Binder WJ. Long-term effects of botulinum toxin type A (Botox) on facial lines: a comparison in identical twins. Arch Facial Plast Surg. 2006;8(6):426-431. PMID 17116793.
Bonaparte JP, Ellis D. Alterations in the Elasticity, Pliability, and Viscoelastic Properties of Facial Skin After Injection of Onabotulinum Toxin A. JAMA Facial Plast Surg. 2015;17(4):256-263. PMID 25996589.
Trindade de Almeida AR, Martins da Costa Marques ER, Contin LA, et al. Long-Term Consecutive OnabotulinumtoxinA Injections for Facial Aesthetic Treatment: A Real-World Study. Dermatol Surg. 2025;51(12):1133-1138. PMID 40497579.
Gostimir M, Liou V, Yoon MK. Safety of Botulinum Toxin A Injections for Facial Rejuvenation: A Meta-Analysis of 9,669 Patients. Ophthalmic Plast Reconstr Surg. 2023;39(1):13-25. PMID 35353777.
Flament F, Bazin R, Laquieze S, et al. Effect of the sun on visible clinical signs of aging in Caucasian skin. Clin Cosmet Investig Dermatol. 2013;6:221-232. PMID 24101874.
Sitohang IBS, Makes WI, Sandora N, et al. Topical tretinoin for treating photoaging: A systematic review of randomized controlled trials. Int J Womens Dermatol. 2022;8(1):e003. PMID 35620028.
Naumann M, Boo LM, Ackerman AH, et al. Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2013;120(2):275-290. PMID 23008029.